B
Byoung Chul Cho
Researcher at Yonsei University
Publications - 570
Citations - 23868
Byoung Chul Cho is an academic researcher from Yonsei University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 57, co-authored 429 publications receiving 15603 citations. Previous affiliations of Byoung Chul Cho include University Health System & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria,Yuichiro Ohe,Johan Vansteenkiste,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Ki Hyeong Lee,Arunee Dechaphunkul,Fumio Imamura,Naoyuki Nogami,Takayasu Kurata,Isamu Okamoto,Caicun Zhou,Byoung Chul Cho,Ying Cheng,Eun Kyung Cho,Pei Jye Voon,David Planchard,Wu Chou Su,Jhanelle E. Gray,Siow-Ming Lee,Rachel Hodge,Marcelo Marotti,Yuri Rukazenkov,Suresh S. Ramalingam +23 more
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Journal ArticleDOI
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takashi Yokoi,Alberto Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Catherine Wadsworth,Giovanni Melillo,Haiyi Jiang,Y. Huang,Phillip A. Dennis,Mustafa Ozguroglu,Pacific Investigators +30 more
TL;DR: Progression‐free survival was significantly longer with durvalumab than with placebo, and safety was similar between the groups, and the secondary end points also favored durvalsumab.
Journal ArticleDOI
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress,Cloud P. Paweletz,Enriqueta Felip,Byoung Chul Cho,Daniel Stetson,Brian Dougherty,Zhongwu Lai,Aleksandra Markovets,Ana Vivancos,Yanan Kuang,Dalia Ercan,Sarah E Matthews,Mireille Cantarini,J. Carl Barrett,Pasi A. Jänne,Geoffrey R. Oxnard +15 more
TL;DR: Analysis of cell-free plasma DNA collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD 9291 provides insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291.
Journal ArticleDOI
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Thanyanan Reungwetwattana,Kazuhiko Nakagawa,Byoung Chul Cho,Manuel Cobo,Eun Kyung Cho,Alessandro Bertolini,Sabine Bohnet,Caicun Zhou,Ki Hyeong Lee,Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Andrew P. Brown,Yuri Rukazenkov,Suresh S. Ramalingam,Johan Vansteenkiste +17 more
TL;DR: Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer and these results suggest a reduced risk of CNS progression with osimert inib versus standard EGFR -TKIs.
Journal ArticleDOI
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun,Lin Shen,Manish A. Shah,Peter C. Enzinger,Antoine Adenis,Toshihiko Doi,Takashi Kojima,Jean-Philippe Metges,Zhigang Li,Sung Bae Kim,Byoung Chul Cho,Wasat Mansoor,Shau-Hsuan Li,Patrapim Sunpaweravong,Maria Alsina Maqueda,Eray Goekkurt,Hiroki Hara,Luis Carlos Moreira Antunes,Christos Fountzilas,Akihito Tsuji,Victor Castro Oliden,Qi Liu,Sukrut Shah,Pooja Bhagia,Ken Kato,Keynote Investigators +25 more
TL;DR: In this paper, the authors compared pembrolizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced oesophageal cancer and Siewert type 1 gastro-oesophagesphageal junction cancer.